SEC Comment Letter 0000000000-24-013678 to NeuroSense Therapeutics Ltd. (NRSN, NRSNW) (CIK 0001875091) (NRSN)
NeuroSense Therapeutics Ltd. (NRSN, NRSNW) (CIK 0001875091)
Date: Dec. 12, 2024 · CIK: 0001875091 · Accession: 0000000000-24-013678
AI Filing Summary & Sentiment
File numbers found in text: 333-283656
Letter
December 12, 2024 Or Eisenberg Chief Financial Officer NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya 4672562 Israel Re:NeuroSense Therapeutics Ltd. Registration Statement on Form F-3 Filed December 6, 2024 File No. 333-283656 Dear Or Eisenberg: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Gary M. Emmanuel, Esq.
Show Raw Text
December 12, 2024
Or Eisenberg
Chief Financial Officer
NeuroSense Therapeutics Ltd.
11 HaMenofim Street, Building B
Herzliya 4672562 Israel
Re:NeuroSense Therapeutics Ltd.
Registration Statement on Form F-3
Filed December 6, 2024
File No. 333-283656
Dear Or Eisenberg:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Gary M. Emmanuel, Esq.